Abstract
The p53 oncosuppressor is strictly maintained in an inactive form under normal conditions, while it is post-translationally activated by a variety of stresses, enacting different protective biological functions. Since one critical issue in cancer gene therapy is tumor specificity, we asked whether the tight p53 regulation applies also to exogenously transferred p53. In principle, this type of regulation could allow p53 gene transfer in both normal and tumor cells to produce detrimental effects only in the latter ones. Here, we report that primary bone marrow cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, with no detectable alterations in any of its compartments. Furthermore, simultaneous infection of leukemia and bone marrow cells depleted the neoplastic contamination, allowing lifelong, disease-free survival of 65% of the transplanted animals. These results show that exogenous p53 is controlled as tightly as the endogenous one, and opens the way to p53 gene therapy, without requiring tumor targeting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Almog N and Rotter V . (1997). Biochim. Biophys. Acta, 1333, F1–F27.
Appella E and Anderson CW . (2000). Pathol. Biol., 48, 227–254.
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Baker DF, Nakamura Y, White R and Volgestein B . (1989). Science, 244, 217–221.
Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S and Sacchi A . (1995). Oncogene, 10, 731–737.
Bodine DM, McDonagh KT, Seidel NE and Nienhuis AW . (1991). Exp. Hematol., 19, 206–212.
Bossi G, Scardigli R, Musiani P, Martinelli R, Gentileschi MP, Soddu S and Sacchi A . (2000). Cancer Gene Ther., 7, 135–143.
Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL and Liu TJ . (1995). Cancer Res., 55, 1–6.
Domen J and Weissman IL . (1999). Mol. Med. Today, 5, 201–208.
D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A and Soddu S . (2000). J. Gene Med., 2, 11–21.
Favrot M, Coll JL, Louis N and Negoescu A . (1998). Gene Therapy, 5, 728–739.
Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA and Serrano M . (2002). EMBO J., 21, 6225–6235.
Gorin NC . (2002). Curr. Opin. Oncol., 14, 152–159.
Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B and Stanbridge EJ . (1992). Mol. Cell. Biol., 12, 1387–1395.
Harris CC . (1996). J. Natl. Cancer Inst., 88, 1442–1455.
Heslop HE, Rooney CM and Brenner MK . (1995). Blood Rev., 9, 220–225.
Karlsson S . (1997). J. Intern. Med., 740 (Suppl.), 95–99.
Kastan MB, Radin AI, Kuerbitz SJ, Onyekwere O, Wolkow CA, Civin CI, Stone KD, Woo T, Ravindranath Y and Craig RW . (1991). Cancer Res., 51, 4279–4286.
LaCasse EC, Bray MR, Patterson B, Lim WM, Perampalam S, Radvanyi LG, Keating A, Stewart AK, Buckstein R, Sandhu JS, Miller N, Banerjee D, Singh D, Belch AR, Pilarski LM and Gariepy J . (1999). Blood, 94, 2901–2910.
Martinelli R, Blandino G, Scardigli R, Crescenzi M, Lombardi D, Sacchi A and Soddu S . (1997). Oncogene, 15, 607–611.
Mazzaro G, Bossi G, Coen S, Sacchi A and Soddu S . (1999). Oncogene, 18, 5831–5835.
Miller AD, Miller DG, Garcia JV and Lynch CM . (1993). Methods Enzymol., 217, 581–599.
Miller AD and Rosman GJ . (1989). BioTechniques, 7, 980–990.
Morgesern JP and Land H . (1990). Nucllic Acids Res., 18, 3587–3596.
Nielsen LL and Maneval DC . (1998). Cancer Gene Ther., 5, 52–63.
Roth JA and Cristiano RJ . (1997). J. Natl. Cancer Inst., 89, 21–39.
Scardigli R, Bossi G, Blandino G, Crescenzi M, Soddu S and Sacchi A . (1997). Gene Therapy, 4, 1371–1378.
Shaulsky G, Goldfinger N, Peled A and Rotter V . (1991). Proc. Natl. Acad. Sci. USA, 88, 8982–8986.
Soddu S, Blandino G, Scardigli R, Martinelli R, Rizzo MG, Crescenzi M and Sacchi A . (1996). Mol. Cell. Biol., 16, 487–495.
Soddu S and Sacchi A . (1998). Cytok. Cell. Mol. Ther., 4, 177–185.
Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R and Minna JD . (1992). Cancer Res., 52, 2340–2343.
Williams DA, Nienhuis AW, Hawley RG and Smith FO . (2000). Hematology (Am. Soc. Hematol. Educ. Program), 376–393.
Wills KN, Mangvai DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM and Gregory RJ . (1994). Hum. Gene Ther., 5, 1079–1088.
Yang S, Delgado R, King SR, Woffendin C, Barker CS, Yang ZY, Xu L, Nolan GP and Nabel GJ . (1999). Hum. Gene Ther., 10, 123–132.
Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG and Roth JA . (1995). Hum. Gene Ther., 6, 155–164.
Acknowledgements
We gratefully acknowledge Ian Pragnell for helpful advice on BM culturing, Gary Nolan for the gift of packaging cells, the Radiation Therapy Department of the Regina Elena Cancer Institute, Marco Scarsella, and Enrico Spugnini for their assistance in the mice irradiation and BM transplantation, and Silvia Bacchetti for critical revision of the manuscript. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Italia–USA project, and Ministero della Salute. GB and AP were recipients of fellowships from the Fondazione Italiana per la Ricerca sul Cancro (FIRC).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bossi, G., Mazzaro, G., Porrello, A. et al. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene 23, 418–425 (2004). https://doi.org/10.1038/sj.onc.1207042
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207042
Keywords
This article is cited by
-
p53 mitotic centrosome localization preserves centrosome integrity and works as sensor for the mitotic surveillance pathway
Cell Death & Disease (2019)
-
The beneficial effect of Zinc(II) on low-dose chemotherapeutic sensitivity involves p53 activation in wild-type p53-carrying colorectal cancer cells
Journal of Experimental & Clinical Cancer Research (2015)
-
Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53
Oncogene (2007)
-
Trials of gene therapy for pancreatic carcinoma
Current Gastroenterology Reports (2005)